Abstract
Asthma is now one of the most common chronic diseases in westernised countries and is characterised by reversible airway obstruction, bronchial hyperresponsiveness and airway inflammation. Key pathological features include: infiltration of the airways by activated lymphocytes and eosinophils; damage to, and loss of, the bronchial epithelium; mast cell degranulation; mucous gland hyperplasia; and collagen deposition in the epithelial sub-basement membrane area. Asthma pathology is associated with the release of myriad pro-inflammatory substances including lipid mediators, inflammatory peptides, chemokines, cytokines, and growth factors. In addition to infiltrating leukocytes, structural cells in the airways, including smooth muscle cells, endothelial cells, fibroblasts and airway epithelial cells, are all important sources of asthma-causing or -enhancing mediators [1]. This complex scenario means that potential targets for therapeutic intervention are many and varied and the task of successful therapy a challenging one.
Keywords
- Chronic Obstructive Pulmonary Disease
- Airway Inflammation
- Severe Asthma
- Airway Smooth Muscle
- Allergy Clin Immunol
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Busse WW, Lemanske RF Jr (2001) Asthma. N Engl J Med 344: 350–362
Holtzman MJ (2003) Drug development for asthma. Am J Respir Cell Mol Biol 29: 163–171
Leung DYM, de Castro M, Szefler SJ, Chrousos GP (1998) Mechanisms of glucocorticoids-resistant asthma. Ann NY Acad Sci 840: 1567–1574
Adcock IM, Lane SJ (2003) Corticosteroid-insensitive asthma: Molecular mechanisms. J Endocrinol 178: 347–355
Celli BR, MacNee W (2004) ATS/ERS Task Force Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 23: 932–946
Jeffery PK (1998) Structural and inflammatory changes in COPD: A comparison with asthma. Thorax 53: 129–136
Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 361: 449–456
Barnes PJ, Ito K, Adcock IM (2004) Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363: 731–733
Ito K, Barnes PJ, Adcock IM (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 18: 6891–6903
Adcock IM, Kazuhiro I (2005) Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc 2: 313–319
Barnes PJ, Adcock IM, Ito K (2005) Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 25: 552–563
Weinbrenner A, Huneke D, Zschiesche M, Engle G, Timmer W, Steinijans VW (2002) Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide J Clin Endocrinol Metab 87: 2160
Taylor DA, Jensen MW, Kanabar V, Engelstatter R, Steinijans VW, Barnes PJ, O’Connor BJ (1999) A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5’-monophosphate in asthmatic patients. Am J Respir Crit Care Med 160: 237
Larsen BB, Nielsen LP, Engelstatter R, Steinijans V, Dahl R (2003) Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 58: 207
Gauvreau GM, Boulet LP, Postma DS, Kawayama T, Watson RM, Duong M, Deschesnes F, De Monchy JG, O’Byrne PM (2005) Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 116: 285
Chapman KR, Patel P, D’Urzo AD, Alexander M, Mehra S, Oedekoven C, Engelsatter R, Boulet LP (2005) Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthm.a Allergy 60: 330
Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 94: 557–752
Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M (1997) Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol 11: 1245–1255
Barnes PJ (2000) New treatments for asthma. Eur J Int Med 11: 9–20
Drazen JM, Israel E, O’Byrne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340: 197–206
Lipworth BJ (1999) Leukotriene-receptor antagonists. Lancet 353: 57–62
Dahlen S-E (2001) 5-lipoxygenase inhibitors. In: TT Hansel, PJ Barnes (eds): New drugs for asthma, allergy and COPD. Karger, Basel, 115–120
Martin RJ, Cicutto LC, Smith HR, Ballard RD, Szefler SJ (1991) Airways inflammation in nocturnal asthma. Am Rev Respir Dis 143: 351–357
Fahy JV, Kim KW, Liu J, Boushey HA (1995) Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 95: 843–852
Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV (2000) Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am J Respir Crit Care Med 161: 1185–1190
Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, Hunt LW, Gleich GJ (1993) Sudden-onset fatal asthma: A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 148: 713–719
Jennewein HM, Anderskewitz R, Meade CJ, Pairet M, Birke F (2001) LTB4 antagonism. In TT Hansel, PJ Barnes (eds): New drugs for asthma, allergy and COPD. Karger, Basel: Karger, 121–125
Gompertz S, Stockley RA (2002) A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 122: 289–294
Groenke L, Beeh KM, Wang JH, Kornmann O, Beier J, Cameron R, Brauburger J, Holz MO, Joerres RA, Shaw M et al (2002) LTB 019A, a leukotriene B4 receptor antagonist, has no effect on the levels of neutrophils, MPO, IL-8 and TNF-alpha in induced sputum of patients with COPD. Am J Respir Crit Care Med 165: A225
Torphy TJ, Compton CH, Marks MJ, Sturton G (2001) Phosphodiesterase 4 inhibitors. In: TT Hansel, PJ Barnes (eds): New drugs for asthma, allergy and COPD. Karger, Basel, 321–325
Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47: 127
Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel anti-asthma agents. Phosphodiesterase isozymes: Molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 157: 351–370
Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT, Minnicozzi M (2001) Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 14: 157
Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R (2006) Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther 19: 343–352
Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC (2001) Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study. Lancet 358: 265
Barnes PJ (1999) Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160: S72–79
Hiemstra PS, van Wetering S, Stolk J (1998) Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: Effects on pulmonary epithelium. Eur Respir J 12: 1200–1208
Blease K, Lewis A, Raymon HK (2003) Emerging treatments for asthma. Expert Opin Emerg Drugs 8: 71
Varney VA, Hamid QA, Gaga M (1993) Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92: 644
Kay AB (2003) Immunomodulation in asthma: mechanisms and possible pitfalls. Curr Opin Pharmacol 3: 220
Jain VV, Businga TR, Kitagaki K, George CL, O’Shaughnessy PT, Kline JN (2003) Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am J Physiol Lung Cell Mol Physiol 285: L1137
Oldfield WL, Larche M, Kay AB (2002) Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial. Lancet 360: 47
Alexander C, Tarzi M, Larché M, Kay AB (2005) The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60: 1269
Chung KF (2001) Cytokines in chronic obstructive pulmonary disease. Eur Respir J (Suppl) 34: 50s–59s
Barnes PJ (2003) Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev 14: 511
Chung KF, Barnes PJ (1999) Cytokines in asthma. Thorax 54: 825–57
Walsh GM (1999) Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 36: 453
Egan RW, Umland SP, Cuss FM, Chapman RW (1996) Biology of interleukin-5 and its relevance to allergic disease. Allergy 51: 71–81
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Conner BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R et al (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 356: 2144–2148
O’Byrne PM, Inman MD, Parameswaran K (2001) The trials and tribulations of IL-5, eosinophils and allergic asthma. J Allergy Clin Immunol 108: 503–508
Lipwoth BJ (2001) Eosinophils and airway hyper-responsiveness. Lancet 357: 1446
Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson D (2003) Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167: 199
Kips JC, O’Conner BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA (2003) Effect of SCH55700, a humanised anti-human interleukin-5 antibody in severe persistent asthma — A pilot study. Am J Respir Crit Care Med 167: 1655–1659
Morokata T, Ida K, Yamada T (2002) Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int Immunopharmacol 2: 1693–1702
Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O’Neill KR, Protheroe C, Pero R, Nguyen T, Cormier SA et al (2004) Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305: 1773
Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, Ghiran S, Gerard NP, Yu C, Orkin SH et al (2004) A critical role for eosinophils in allergic airways remodelling. Science 305: 1776
Wenzel SE, Schwartz LB, Langmac EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160: 1001–1008
Balzar S, Chu HW, Silkoff P, Cundall M, Trudeau JB, Strand M, Wenzel S (2005) Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol 115: 110
Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB (2003) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112: 1029–36
Kay AB (2003) Eosinophils and IL-5 — The debate continues. Am J Respir Crit Care Med 167: 1586
Domachowske JB, Bonville CA, Easton AJ, Rosenberg HF (2002) Pulmonary eosinophilia in mice devoid of interleukin 5. J Leukoc Biol 71: 966
Jiang H, Harris MB, Rothman P (2000) IL-4/IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol 105: 1063–1070
Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L (1999) Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 160: 1816–1823
Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W (1996) Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: Relationship to interleukin-4 and eosinophil counts. Eur Respir J 9: 899–904
Humbert M, Durham SR, Kimmitt P Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ (1997) Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99: 657–665
Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282: 2261–2282
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD (1998) Interleukin-13: Central mediator of allergic asthma. Science 282: 2258–2260
Hahn C, Teufel M, Herz U, Renz H, Erb KJ, Wohlleben G, Brocker EB, Duschl A, Sebald W, Grunewald SM (2003) Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma J Allergy Clin Immunol 111: 1361–1369
Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ et al (2000) IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma. J Allergy Clin Immunol 105: 108–115
Gounni AS, Gregory B, Nutku E, Aris F, Latifa K, Minshall E, North J, Tavernier J, Levit R, Nicolaides N et al (2000) Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 96: 2163
Temann UA, Ray P, Flavell RA (2002) Pulmonary overexpression of IL-9 induces Th2cytokine expression, leading to immune pathology. J Clin Invest 109: 29–39
Zhou Y, McLane M, Levitt RC (2001) Interleukin-9 as a therapeutic target for asthma. Respir Res 2: 80–84
Keatings VM, Collins PD, Scott DM, Barnes PJ (1996) Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153: 530
Siddiqui MA, Scott LJ (2005) Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. Drugs 65: 2179–2208
Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59: 1341
Barlaam B, Bird TG, Lambert-Van der Brempt C, Campbell D, Foster SJ, Maciewicz R (1999) New alpha-substituted succinate-based hydroxamic acids as TNFalpha conver-tase inhibitors. J Med Chem 42: 4890
Rabinowitz MH, Andrews RC, Becherer JD, Bickett, DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert et al (2001) Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem 44: 425
John M, Lim S, Seybold J, Robichaud A, O’Connor B, Barnes PJ, Chung KF (1998) Inhaled corticosteroids increase IL-10 but reduce MIP-1α, GM-CSF and IFN-γ release from alveolar macrophages in asthma. Am J Respir Crit Care Med 157: 256–26
Borish L, Aarons J, Rumbyrt P, Cvietusa, J, Negri S, Wenzel SE (1996) Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 97: 1288–1296
Hawrylowicz CM, O’Garra A (2005) Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5: 271
Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B (2000) Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology 119: 1473–1482
Matsumoto K, Inoue H, Tsuda M, Honda Y, Kibe A, Machida K, Yoshiura Y, Nakanishi Y (2005) Different roles of interleukin-10 in onset and resolution of asthmatic responses in allergen-challenged mice. Respirology 10: 18
Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K, Okamura K (1999) Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 14: 309
Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM (1995) IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96: 2304–2310
Simon H-U, Seelbach H, Ehmann R, Schmitz M (2003) Clinical and immunological effects of low-dose IFN-α treatment in patients with corticosteroid-resistant asthma. Allergy 58: 1250–1255
Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun V, Laviolette M, Cleland LD, Deschesnes F et al (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155: 1835–1840
Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick, RB, Boushey HA (1997) The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828–1834
Busse WW (2001) Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 164: S12–S17
Milgrom H, Fick RB, Su J, Reimann JD, Bush RK, Watrous ML, Metzger WJ (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341: 1966–1973
Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe asthma. J Allergy Clin Immunol 108: 184–190
Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18: 254–261
Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 23: 76–81
Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 23: 76–81
Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S et al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309
Wardlaw AJ (1999) Molecular basis for selective eosinophil trafficking in asthma: A mulitstep paradigm J Allergy Clin Immunol 104: 917
Walsh GM, Mermod JJ, Hartnell A, Kay AB, Wardlaw AJ (1991) Human eosinophil, but not neutrophil, adherence to IL-1 stimulated HUVEC is α4β1 (VLA-4) dependent. J Immunol 146: 3419–3423
Moser R, Fehr J, Bruijnzeel PB (1992) IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 149: 1432–1438
Thornhill MH, Kyan-Aung U Haskard DO (1990) IL-4 increases human endothelial cell adhesiveness for T cells but not neutrophils. J Immunol 144: 3060.
Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15
Kudlacz E, Whitney C, Andersen C, Duplantier A, Beckius G, Chupak L, Klein A, Kraus K, Milici A (2002) Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists. J Pharmacol Exp Ther 301: 747
Ulbrich H, Eriksson EE, Lindbom L (2003) Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24: 609
Berger JR, Koralnik IJ (2005) Progressive multifocal leukoencephalopathy and natalizumab — Unforeseen consequences. N Engl J Med 353: 414–416
Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GI, Rao P, Ponath PD, Baggiolini M, Dahinden CA (1997) High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 100: 1137
Romagnani P, De Paulis A, Beltrame C, Annunziato F, Dente V, Maggi E, Romagnani S, Marone G (1999) Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol 155: 1195
Sallusto F, Mackay CR, Lanzavecchia A (1997) Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277: 2005
Stellato C, Brummet ME, Plitt JR, Shahabuddin S, Baroody FM, Liu MC, Ponath, Beck LA (2001) Expression of the C-C chemokines receptor CCR3 in human airway epithelial cells. J Immunol 166: 1457
Erin EM, Williams TJ, Barnes PJ, Hansel TT (2002) Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Inflamm Allergy 1: 201–214
De Lucca GV, Kim UT, Johnson C, Vargo BJ, Welch PK, Covington M, Davies P, Solomon KA, Newton RC, Trainor GL et al (2002) Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. J Med Chem 45: 3794
Palframan RT, Collins PD, Williams TJ, Rankin SM (1998) Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 91: 2240
Duncan CJA, Lawrie A, Blaylock MG, Douglas JG, Walsh GM (2003) Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J 22: 484–490
Vignola AM, Chanez P, Chiappara G, Siena L, Merendino A, Reina C, Gagliardo R, Profita M, Bousquet J, Bonsignore G (1999) Evaluation of apoptosis of eosinophils, macrophages and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 103: 563–573
Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley J. (1996) Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med 154: 237–243
Walsh GM (2000) Eosinophil apoptosis: mechanisms and clinical relevance in asthmatic and allergic inflammation. Br J Haematol 111: 61–67
Gounni AS, Gregory B, Nutku E, Aris F, Latifa K, Minshall E, North J, Tavernier J, Levit R, Nicolaides N et al (2000) Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 96: 2163–2171
Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC Jr, Kroegel C (1996) Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relarossitionship to messenger RNA expression, and promotion of cellular viability. J Immunol 157: 1678–1683
Hoontrakoon R, Chu HW, Gardai SJ, Wenzel SE, McDonald P, Fadok VA, Henson PM, Bratton DL (2002) Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via autocrine production of granulocyte macrophage-colony stimulating factor and nuclear factor-κB activation. Am J Respir Cell Mol Biol 26: 404–412
Anwar ARE, Moqbel R, Walsh GM, Kay AB, Wardlaw AJ (1993) Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 177: 839–843
Walsh GM, Symon FA, Wardlaw AJ (1995) Human eosinophils preferentially survive on tissue fibronectin compared with plasma fibronectin. Clin Exp Allergy 25: 1128–1136
Temkin V, Levi-Shaeffer F (2001) Mechanisms of tumour necrosis factor alpha mediated eosinophil survival. Cytokine 15: 20
Fujihara S, Ward C, Dransfield I, Hay RT, Uings IJ, Hayes B, Farrow SN, Haslett C, Rossi AG (2002) Inhibition of nuclear factor-kappa B activation un-masks the ability of TNF-alpha to induce human eosinophil apoptosis. Eur J Immunol 32: 457
Gagliardo R, Chanez P, Mathieu M, Bruno A, Costanzo G, Gougat C, Vachier I, Bousquet J, Bonsignore G, Vignola AM (2003) Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med 168: 1190–1198
Meagher LC, Cousin JM, Seckl JR, Haslett C (1996) Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156: 4422–4428
Saunders MW, Wheatley AH, George SJ, Lai T, Birchall MA (1999) Do corticosteroids induce apoptosis in nasal polyp inflammatory cells? In vivo and in vitro studies. Laryngoscope 109: 785–790
Nutku E, Zhuang Q, Soussi-Gounni A, Aris F, Mazer BD, Hamid Q (2001) Functional expression of IL-12 receptor by human eosinophils: IL-12 promotes eosinophil apoptosis. J Immunol 167: 1039–1046
Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, Hamid Q (1997) Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 155: 845–851
Bryan SA, O’Conner BJ, Matti S, Leckie MJ, Kanabar V, Khan J, Warrington SJ, Renzetti L, Rames A, Bock JA et al (2000) Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2149–2153
Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS (1995) Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 86: 1437–1443
Druilhe A, Cai Z, Haile S, Chouaib S, Pretolani M (1996) Fas-mediated apoptosis in cultured human eosinophils. Blood 87: 2822–2830
Walsh GM, Williamson ML, Symon FA, Wilars GB, Wardlaw AJ (1996) Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with GM-CSF. Blood 87: 2815–2821
Nutku E, Aizawa H, Hudson SA, Bochner BS (2003) Ligation of Siglec-8: A selective mechanism for induction of human eosinophil apoptosis. Blood 101: 5014–5020
Blaylock MG, Sexton DW, Walsh GM (1999) Ligation of CD45 and the isoforms CD45RA and CD45RB accelerates the rate of constitutive apoptosis in human eosinophils. J Allergy Clin Immunol 104: 1244–1250
Blaylock MG, Lipworth BJ, Dempsey OJ, Duncan CJ, Lee DK, Lawrie A, Douglas JG, Walsh GM (2003) Eosinophils from patients with asthma express higher levels of the pan-leucocyte receptor CD45 and the isoform CD45RO. Clin Exp Allergy 33: 936–941
Druihle A, Letuve S, Petolani M (2003) Glucocorticoid-induced apoptosis in human eosinophils: Mechanisms of action. Apoptosis 8: 481–495
Zangirilli J, Robertson N, Shetty A, Wu J, Hastie A, Fish JE, Litwack G, Peters SP (2000) Effect of IL-5, glucocorticoid, and Fas ligation on Bcl-2 homologue expression and caspase activation in circulating human eosinophils. Clin Exp Immunol 120: 12–21
Zhang JP, Wong CK, Lam WK (2000) Role of caspases in dexamethasone-induced apoptosis and activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in human eosinophils. Clin Exp Immunol 122: 20–27
Al-Rabia MW, Blaylock MG, Sexton DW, Walsh GM (2004) Membrane receptor mediated apoptosis and caspase activation in the differentiated EoL-1 eosinophilic cell line. J Leukoc Biol 75: 1045–55
Gardai SJ, Hoontrakoon R, Goddard CD, Day BJ, Chang LY, Henson PM, Bratton DL (2003) Oxidant-mediated mitochondrial injury in eosinophil apoptosis: Enhancement by glucocorticoids and inhibition by granulocyte-macrophage colony-stimulating factor. J Immunol 170: 556–566
Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: A discourse on the Bcl-2 family and cell death. Blood 88: 386–410
Ochiai K, Kagami M, Matsumura R, Thmioka H (1997) IL-5 but not interferon-gamma inhibits eosinophil apoptosis by upregulation of Bcl-2 expression. Clin Exp Immunol 107: 198–204
Druilhe A, Arock M, Le Goff L, Pretolani M (1998) Human eosinophils express Bcl-2 family proteins: Modulation of Mcl-1 expression by IFN-gamma. Am J Respir Cell Mol Biol 18; 315–322
Dewson G, Walsh GM, Wardlaw AJ (1999) Expression of Bcl-2 and its homologues in human eosinophils: Modulation by interleukin-5. Am J Respir Cell Mol Biol 20: 720–728
Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K. Levi-Schaffer F, Anderson GP (1998) Role for Bcl-XL in delayed eosinophil apoptosis mediated by granulocytemacrophage colony-stimulating factor and interleukin-5. Blood 92: 778–783
Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407: 784–788
Vandivier, RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, Henson PM (2002) Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 109: 661
Stern M, Savill J, Haslett C (1996) Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis: mediation by αvβ3/CD36/thrombospondin recognition mechanisms and lack of phlogistic response. Am J Pathol 149: 911–921
Platt N, da Silva RP, Gordon S (1998) Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol 8: 356–372
Walsh GM, Sexton DW, Blaylock MG, Convery CM (1999) Resting and cytokine-stimulated human small airway epithelial cells recognize and ingest apoptotic eosinophils. Blood 94: 2827–2835
Sexton DW, Blaylock MG, Walsh GM (2001) Human alveolar epithelial cells engulf apoptotic eosinophils via integrin-and phosphatidylserine-dependent mechanisms: A process upregulated by dexamethasone. J Allergy Clin Immunol 108: 962–969
Sexton DW, Blaylock MG, Al-Rabia M, Walsh GM (2004) Phagocytosis of apoptotic eosinophils but not neutrophils by bronchial epithelial cells. Clin Exp Allergy 34: 1514–1524
Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, Wenzel SE (2005) Defective apoptotic cell phagocytosis attenuates prostaglandin e2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 172: 972–979
Erjefalt JS, Uller L, Malm-Erjefalt M, Persson CG (2004) Rapid and efficient clearance of airway tissue granulocytes through transepithelial migration. Thorax 59: 136–43
Uller L, Persson CG, Kallstrom L, Erjefalt JS (2001) Lung tissue eosinophils may be cleared through luminal entry rather than apoptosis: Effects of steroid treatment. Am J Respir Crit Care Med 164: 1948–1956
Erjefält JS, Persson CGA (2000) New aspects of degranulation and fates of airway mucosal eosinophils. Am J Respir Crit Care Med 161: 2074–2085
Hughes J, Johnson RJ, Mooney A, Hugo C, Gordon K, Savill J (1997) Neutrophil fate in experimental glomerular capillary injury in the rat. Emigration exceeds in situ clearance by apoptosis. Am J Pathol 150: 223
Brazil TJ, Dagleish MP, McGorum BC, Dixon PM, Haslett C, Chilvers ER (2005) Kinetics of pulmonary neutrophil recruitment and clearance in a natural and spontaneously resolving model of airway inflammation. Clin Exp Allergy 35: 854–865
Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, Wenzel SE (2005) Epithelial cells as phagocytes: Apoptotic epithelial cells are engulfed by mammary alveolar epithelial cells and repress inflammatory mediator release. Am J Respir Crit Care Med 172: 972–979
Corry DB, Kiss A, Song LZ, Song L, Xu J, Lee SH, Werb Z, Kheradmand F (2004) Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J 18: 995–997
Brightling C, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID (2002) Mastcell infiltration of airway smooth muscle in asthma. N Engl J Med 346: 1699–1705
Brightling C, Symon F, Holgate S, Wardlaw A, Pavord I, Bradding P (2003) Interleukin-4 and-13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 33: 1711–1716
Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y et al (2000) Prostaglandin D2 as a mediator of allergic asthma. Science 287: 2013
Monneret G, Gravel S, Diamond M, Rokach J, Powell WS (2001) Prostaglandin D2 is a potent chemoattractant for eosinophils that acts via a novel DP receptor. Blood 98: 1942
Kamath AV, Pavord ID, Ruparelia PR, Chilvers ER (2005) Is the neutrophil the key effector cell in severe asthma? Thorax 60: 529–530
Kogan TP, Dupre B, Bui H, McAbee KL, Kassir JM, Scott IL, Hu X, Vanderslice P, Beck PJ, Dixon RA (1998) Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyloxy)phenyl] hexane (TBC1269). J Med Chem 41: 1099–1111
Abraham WM, Ahmed A, Sabater JR, Lauredo IT, Botvinnikova Y, Bjercke RJ, Hu X, Revelle BM, Kogan TP, Scott IL (1999) Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med 159: 1205–1214
Avila PC, Boushey HA, Wong H, Grundland H, Liu J, Fahy JV (2004) Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses. Clin Exp Allergy 34: 77–84
Beeh KM, Beier J, Buhl R, Zahlten R, Wolff G (2004) Influence of inhaled Bimosiamose (TBC1269), a synthetic pan-selectin antagonist, on the allergen-induced late asthmatic response (LAR) in patients with mild allergic asthma. Am J Respir Crit Care Med 169: A321
Repine JE, Bast A, Lankhorst I (1997) Oxidative stress in chronic obstructive pulmonary disease Oxidative Stress Study Group. Am J Respir Crit Care Med 156: 341–357
Beeh KM, Beier J (2005) Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma? Clin Exp Allergy 36: 142–157
Thomas CE, Ohlweiler DF, Carr AA, Nieduzak TR, Hay DA, Adams G, Vaz R, Bernotas RC (1996) Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J Biol Chem 271: 3097–3104
Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokuyama T, Tsukaguchi K, Narita N (1997) Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 112: 505–510
Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA (2000) Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 55: 114–120
Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG (1999) Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 66: 401–410
White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, Sarau HM (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273: 10095–10098
Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M (2003) Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 81: 289
Heasman SJ, Giles KM, Ward C, Rossi AG, Haslett C, Dransfield I (2003) Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: Implications for the resolution of inflammation. J Endocrinol 178: 29
Lee E, Lindo T, Jackson N, Meng-Choong L, Reynolds P, Hill A, Haswell M, Jackson S, Kilfeather S (1999) Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 160: 2079
Hannah S, Mecklenburgh K, Rahman I, Bellingan GJ, Greening A, Haslett C, Chilvers ER (1995) Hypoxia prolongs neutrophil survival in vitro. FEBS Lett 372: 233
Webb PR, Wang KQ, Scheel-Toellner D, Pongracz J, Salmon M, Lord JM (2000) Regulation of neutrophil apoptosis: A role for protein kinase C and phosphatidylinositol-3-kinase. Apoptosis 5: 451
Sexton DW, Walsh GM (2005) Airway inflammation resolution: ‘Must not all things at the last be swallowed up in death?’ Clin Exp Allergy 35: 838–840
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Walsh, G.M., McDougall, C.M. (2008). The resolution of airway inflammation in asthma and chronic obstructive pulmonary disease. In: Rossi, A.G., Sawatzky, D.A. (eds) The Resolution of Inflammation. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7506-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7506-5_9
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7505-8
Online ISBN: 978-3-7643-7506-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)